Pharmacological Profile of GPD-1116, an Inhibitor of Phosphodiesterase 4-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacological Profile of GPD-1116, an Inhibitor of Phosphodiesterase 4

Published:2016 Issue:5 Volume:39 Page:689-698
ISSN:0918-6158
Container-title:Biological & Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Nose Takashi¹,Kondo Miwa²,Shimizu Masashi³,Hamura Hiroki¹,Yamaguchi Yusuke⁴,Sekine Takako¹,Ishitani Kouki⁵

Affiliation:

1. Pharmacological Research Department, ASKA Pharmaceutical Co., Ltd.

2. Clinical Development Department II, Research and Development Division, ASKA Pharmaceutical Co., Ltd.

3. Pharma Business Planning Department, Pharma Business Division, ASKA Pharmaceutical Co., Ltd.

4. Drug Discovery Department, ASKA Pharmaceutical Co., Ltd.

5. Research Planning and Management Department, Research and Development Division, ASKA Pharmaceutical Co., Ltd.

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/39/5/39_b15-00652/_pdf

Reference41 articles.

1. 1) Boswell-Smith V, Spina D, Page CP. Phosphodiesterase inhibitors. Br. J. Pharmacol., 147 (Suppl. 1), S252–S257 (2006).

2. 2) Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat. Rev. Drug Discov., 13, 290–314 (2014).

3. 3) Corbin JD, Francis SH, Webb DJ. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology, 60 (Suppl. 2), 4–11 (2002).

4. 4) Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, Humbert M, Simonneau G, Sitbon O. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv. Ther., 26, 813–825 (2009).

5. 5) Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med. Princ. Pract., 19, 330–338 (2010).

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension;Acta Pharmaceutica Sinica B;2024-04

2. Advances in targeting Phosphodiesterase 1: From mechanisms to potential therapeutics;European Journal of Medicinal Chemistry;2024-01

3. Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases;European Journal of Medicinal Chemistry;2022-11

4. The regulatory role of PDE4B in the progression of inflammatory function study;Frontiers in Pharmacology;2022-10-06

5. New Therapeutic Targets in Neonatal Pulmonary Hypertension;Newborn;2022-03-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3